Insmed - INSM Stock Forecast, Price & News

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

Insmed Price Performance

Shares of NASDAQ:INSM traded up $0.14 on Monday, hitting $27.40. The company's stock had a trading volume of 1,004,707 shares, compared to its average volume of 1,074,456. Insmed has a 12-month low of $16.41 and a 12-month high of $34.44. The company has a market capitalization of $3.29 billion, a price-to-earnings ratio of -7.83 and a beta of 1.91. The company has a debt-to-equity ratio of 18.65, a current ratio of 5.93 and a quick ratio of 5.34. The stock has a 50 day moving average of $21.90 and a 200-day moving average of $22.19.

Insmed (NASDAQ:INSM - Get Rating) last announced its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.80) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.89) by $0.09. Insmed had a negative net margin of 188.04% and a negative return on equity of 154.14%. The company had revenue of $65.20 million for the quarter, compared to the consensus estimate of $58.92 million. During the same quarter in the prior year, the firm earned ($0.94) earnings per share. The company's revenue for the quarter was up 43.6% compared to the same quarter last year. As a group, research analysts predict that Insmed will post -3.4 EPS for the current year.

Analysts Set New Price Targets

Several research analysts have weighed in on the stock. Morgan Stanley lowered their target price on shares of Insmed from $46.00 to $41.00 and set an "overweight" rating on the stock in a research report on Friday, July 15th. The Goldman Sachs Group lowered their target price on shares of Insmed from $56.00 to $48.00 and set a "buy" rating on the stock in a research report on Tuesday, May 24th. Finally, Credit Suisse Group upped their target price on shares of Insmed to $58.00 in a research report on Tuesday, August 9th. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $50.86.

Insider Activity at Insmed

In related news, CEO William Lewis sold 216,800 shares of the company's stock in a transaction that occurred on Monday, August 8th. The shares were sold at an average price of $27.84, for a total transaction of $6,035,712.00. Following the transaction, the chief executive officer now owns 256,716 shares of the company's stock, valued at $7,146,973.44. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Over the last 90 days, insiders have sold 314,355 shares of company stock valued at $8,279,853. Company insiders own 4.40% of the company's stock.